Venetoclax
Showing 1 - 25 of 352
Acute Myeloid Leukemia Trial in Nanjing (Venetoclax-Decitabine/Azacitidine-Aclarubicin Association,
Recruiting
- Acute Myeloid Leukemia
- Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
- Venetoclax-Decitabine/Azacitidine Association
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Mar 2, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Obinutuzumab, Rituximab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Venetoclax
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jun 1, 2022
Chronic Myeloid Leukemia Trial in Jena (Venetoclax)
Not yet recruiting
- Chronic Myeloid Leukemia
- Venetoclax
-
Jena, GermanyUniversitätsklinikum Jena
Jan 17, 2023
Acute Myeloid Leukemia, Measurable Disease Trial in Tianjin (Venetoclax, Azacitidine, Venetoclax, daunorubicin, cytarabine)
Recruiting
- Acute Myeloid Leukemia
- Measurable Disease
- Venetoclax, Azacitidine
- Venetoclax, daunorubicin, cytarabine
-
Tianjin, Tianjin, ChinaHBDH
Apr 28, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Decitabine
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 15, 2022
Hemophagocytic Lymphohistiocytosis Trial in Beijing (Venetoclax, Dexamethasone, Etoposide)
Recruiting
- Hemophagocytic Lymphohistiocytosis
- Venetoclax
- +2 more
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Sep 15, 2022
Secondary Acute Myeloid Leukemia Trial in Nanjing (Venetoclax;Azacitidine;Homoharringtonine)
Recruiting
- Secondary Acute Myeloid Leukemia
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Aug 21, 2022
Chronic Lymphocytic Leukemia Trial (Venetoclax)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Venetoclax
- (no location specified)
Apr 2, 2022
AL Amyloidosis Trial in New York (Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg)
Not yet recruiting
- AL Amyloidosis
- Venetoclax Oral Tablet, 200 mg
- +9 more
-
New York, New YorkNew York Presbyterian Hospital/Columbia University Irving Medica
Jul 11, 2022
Acute Myeloid Leukemia Trial in Suzhou (Azacitidine Combined With Venetoclax and ATRA group)
Recruiting
- Acute Myeloid Leukemia
- Azacitidine Combined With Venetoclax and ATRA group
-
Suzhou, Chinathe First Affiliated Hospital of Soochow University
Dec 8, 2022
Waldenstrom Macroglobulinemia Trial (Venetoclax; Rituximab, DRC)
Not yet recruiting
- Waldenstrom Macroglobulinemia
- Venetoclax; Rituximab
- DRC
- (no location specified)
Jul 27, 2022
Acute Myeloid Leukemia Trial (with or without venetoclax)
Not yet recruiting
- Acute Myeloid Leukemia
- with or without venetoclax
- (no location specified)
Apr 29, 2022
Myelodysplastic/Myeloproliferative Tumors, Adult Trial in Suzhou (venetoclax combined with azacitidine)
Enrolling by invitation
- Myelodysplastic/Myeloproliferative Neoplasms
- Adult
- venetoclax combined with azacitidine
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Mar 7, 2022
Acute Myeloid Leukemia Trial in Beijing (azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte)
Recruiting
- Acute Myeloid Leukemia
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Dec 13, 2022
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)
Recruiting
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Olverembatinib
- +3 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Oct 21, 2022
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)
Active, not recruiting
- Waldenstrom Macroglobulinemia
- MYD88 Gene Mutation
- IBRUTINIB
- Venetoclax
-
Boston, Massachusetts
- +1 more
Apr 1, 2022
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Venetoclax
- Tazemetostat
-
New York, New YorkWeill Cornell Medicine/NewYork-Presberteryian Hospital
Jan 18, 2023
Mantle Cell Lymphoma Trial in Baltimore (Venetoclax Oral Tablet [Venclexta])
Recruiting
- Mantle Cell Lymphoma
- Venetoclax Oral Tablet [Venclexta]
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jun 29, 2022
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease Trial (Venetoclax, Decitabine,
Not yet recruiting
- Relapsed Acute Myeloid Leukemia
- +2 more
- Venetoclax, Decitabine, Azacytidine, Cytarabine
- (no location specified)
May 4, 2022
Venetoclax in Patients With Acute Myeloid Leukemia
Recruiting
- Acute Myeloid Leukemia
- Venetoclax
-
Taipei, TaiwanNational Taiwan University Hospital
Oct 27, 2021
High Risk CLL, Chronic Lymphocytic Leukemia Trial (VenObi+Ven or VenObi+VenZan)
Not yet recruiting
- High Risk CLL
- Chronic Lymphocytic Leukemia
- VenObi+Ven or VenObi+VenZan
- (no location specified)
Jul 26, 2022
Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Lintuzumab-Ac225
- +2 more
- (no location specified)
Feb 22, 2022